A substantial body of evidence from observational studies, experimental models, and clinical trials has accumulated during the past 30 years in support of the hypothesis that increasing intake of long-chain n-3 polyunsaturated fatty acids (PUFAs) from fish may protect against lethal ventricular arrhythmias in the setting of coronary heart disease (CHD). 1 Beginning in the 1980s, these fatty acids conferred protection against ventricular fibrillation in the setting of ischemia in animal models [2] [3] [4] [5] ; experimental studies subsequently uncovered plausible electrophysiological mechanisms to explain these antiarrhythmic effects, including modulation of ion channels and the autonomic nervous system. 1, 6 The study by Billman et al 7 in this issue of Circulation, Arrhythmia and Electrophysiology set out to confirm these antiarrhythmic effects in a canine postmyocardial infarction (MI) model of sudden cardiac death (SCD); however, the results were not as expected.
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In 2 independent laboratories, dietary supplementation with n-3 PUFAs did not protect against ventricular arrhythmias. The first laboratory did not find suppression of ischemia-mediated ventricular fibrillation (VF) in 8 VF-susceptible dogs after 8 weeks of n-3 PUFA at a dose of 1 g/d. The second laboratory used a more complicated dose-ranging protocol, with n-3 PUFA doses of 1, 2, and 4 g and a corn oil placebo. There was a fairly high rate of unexpected spontaneous death (19%) in both the active and placebo treatment arms in dogs that exhibited exercise-induced VF, which was not seen in the first laboratory nor in prior work examining intravenous n-3 PUFAs in the same animal model. 4, 5 These deaths were considered to be arrhythmic events, but continuous electrocardiographic monitoring was not performed, so the mechanism remains uncertain. The outcome in the second study was an arrhythmia severity score, which incorporated these spontaneous deaths by assigning the highest score to these events. The score also included non-life-threatening arrhythmias, such as premature ventricular contractions and nonsustained ventricular tachycardia (VT), and the end point of exercise-induced VF used in the prior study. Treatment with n-3 PUFAs or placebo did not reduce the arrhythmia score in VF-susceptible dogs, as initially hypothesized.
In addition to a lack of a demonstrable antiarrhythmic effect in high-risk animals, a possible proarrhythmic effect was observed in lower-risk animals. Dogs that did not previously exhibit exercise-induced VF had a higher incidence of arrhythmias after treatment with n-3 PUFA compared with placebo, with 3 dogs experiencing VF with exercise in the highest dosing category (4 g). Two spontaneous deaths were also observed in sham dogs treated with 4 g of n-3 fatty acids. Although there was no control group, such spontaneous deaths in this model had not previously been reported. The authors conclude from these data that dietary supplementation with n-3 PUFA significantly increases the susceptibility to malignant arrhythmias in these dogs.
These findings are in direct contrast with those of a prior study by some of the same authors using intravenous, rather than dietary, administration of n-3 PUFA in the same canine SCD model. 4, 5 Although the prior study did not specifically test for a proarrhythmic effect in VF-resistant dogs, intravenous infusions of n-3 PUFA conferred strong protection against VF in VF-susceptible dogs, 4,5 which was clearly not demonstrated with dietary supplementation in either of the present studies. Although no direct mechanism is provided to explain these disparate findings, these data raise the possibility that the mode of administration of n-3 PUFA and/or the total accumulated dose might influence the summation of electrophysiological actions. In experimental models, n-3 PUFAs have differing effects on repolarization, action potential duration, sodium channel blockade, and intracellular calcium handling, depending on whether the fatty acids are circulating (intravenous administration) or incorporated into cell membranes (dietary administration). 8 Most of the potential proarrhythmic events in the present study were observed at the highest 4-g dose. Although the authors state that all 3 doses had similar effects on the susceptibility to VF, this is difficult to critically evaluate given the few dogs in each dosing category and the limited number of hard events. Therefore, the possibility that the electrophysiological properties of n-3 PUFAs may differ at high versus low doses cannot be excluded.
It is important to emphasize that the findings regarding proarrhythmia are based on small numbers of animals and events and, as a result, are of marginal statistical significance (P=0.044). Therefore, chance cannot be entirely excluded as a possible explanation for the findings. In addition, this work needs to be placed in the context of prior animal studies, which, for the most part, have reported either protective or null effects on ventricular arrhythmias with n-3 PUFA dietary supplementation. 9 However, this study is not entirely in isolation either. 8, 10 There are other experimental studies that support the concept that n-3 PUFAs, similar to traditional antiarrhythmic drugs, may facilitate ventricular arrhythmias under certain conditions. 8 The question remains as to how these experimental data might translate to humans. What is the evidence from human studies that these fatty acids can precipitate ventricular arrhythmias?
Similar to the animal data, most studies in humans suggest either a protective or a null effect of dietary or supplemental intake of n-3 PUFA on ventricular arrhythmias or SCD. The data in support of an antiarrhythmic effect in humans are primarily derived from observational studies [11] [12] [13] [14] and early randomized trials, 15, 16 which reported protective associations with SCD that were stronger than that observed for other cardiovascular disease end points. In primarily healthy populations, consuming fish ≈1 to 2 times per week (≈200 mg n-3 PUFA) has been associated with significant 42% to 50% reductions in SCD risk in 4 separate studies. [11] [12] [13] [14] In 2 of these populations, individuals in the highest quartile of n-3 PUFA blood level had 81% to 90% reductions in SCD risk compared with those in the lowest quartile. 14, 17 In the GISSI Prevenzione trial [Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto miocardico], a supplement of 850 mg n-3 PUFA lowered SCD risk in a large, openlabel, randomized trial among 11324 patients after MI. 16 The patients assigned to n-3 PUFA had a significant 15% reduction in the primary end point (death, nonfatal MI, or nonfatal stroke), primarily because of a statistically significant reduction in SCD (45%), without any benefit on nonfatal MI or stroke. 18 The total mortality was significantly lower after 3 months of treatment, and the reduction in risk of SCD was already statistically significant at 4 months (relative risk, 0.47; P=0.048). 18 However, not all human data on n-3 PUFAs are supportive of these postulated antiarrhythmic properties, and there are a couple of studies that do raise concerns regarding the potential for proarrhythmia. The DART-2 trial [Diet and Reinfarction Trial], which was conducted among 3114 men with self-reported "chronic angina" found a paradoxical 26% higher risk of cardiac death and a 54% increased risk of SCD among men randomly assigned to take up to 3 g of fish oil or consume 2 portions of oily fish per week. 19 The total mortality was not significantly increased in the dietary advice arm. This trial had some design issues, including an interruption of the study for 1 year because of inadequate funds requiring rerandomization of participants and followup of participants through a central register in the second phase of the trial. The elevated risk of SCD was only seen in the second phase of the trial, primarily among those advised to take fish oil. It is unclear how these design issues might have influenced other dietary patterns, lifestyle habits, loss to follow-up rates, and SCD confirmation; but it is likely to have had some impact on the validity of the results.
The second study that raised concerns regarding proarrhythmia was performed among patients with implantable cardioverter defibrillators (ICDs) who had a history of VT/VF. Three randomized trials were performed in this patient population at high risk for recurrent ventricular arrhythmias as a "proof of concept" that n-3 PUFAs protect against SCD through antiarrhythmic effects and suppression of VT/VF. All 3 trials failed to show a significant effect of n-3 PUFA supplementation on the risk of ICD therapy for ventricular arrhythmias. [20] [21] [22] Although 1 trial 21 found a trend toward an overall reduction in device therapy for ventricular arrhythmias, another trial 20 unexpectedly raised the possibility of proarrhythmia among a specific subgroup of patients. The latter study by Raitt et al 20 found an unexpected increase in the risk of ICD therapy for ventricular arrhythmias with 1.8 g of n-3 PUFA supplementation among a subgroup of patients whose qualifying arrhythmia was VT, in whom fixed scar reentry, rather than ischemia, might predominate. As with any subgroup finding, one must be cautious not to overinterpret the finding, which could be the result of chance. In addition, it has since become well recognized that an ICD therapy for ventricular arrhythmia does not equate with SCD in randomized trials, 23, 24 and such trials in patients with ICDs cannot substitute for those with SCD and total mortality end points.
There have since been 4 randomized trials of n-3 PUFAs that have examined SCD and total mortality as end points. All have been unable to replicate the initially promising results of the GISSI Prevenzione trial. 16 Two randomized trials 25, 26 performed in post-MI populations failed to demonstrate a benefit on SCD or CHD mortality in a more contemporary era of modern pharmacotherapy. These trials were smaller, and the SCD rate was much lower than had been observed in the GISSI Prevenzione trial. 16 As a result, these trials were significantly underpowered to detect even moderate-tolarge reductions in SCD. The larger of the 2 trials, the Alpha Omega Trial, also used a lower dose (400 mg) of n-3 PUFA and included other events, such as ICD implantation, in the ventricular arrhythmic event end point. 25 Another trial 27 performed among 18645 hypercholesterolemic Japanese patients treated with statins only documented 44 SCD events during a mean follow-up of 4.6 years. The only trial that was adequately powered to detect a clinically meaningful reduction in SCD was the recent GISSI-HF trial. 28 The study population was a heterogeneous heart failure population, which differed from prior trial populations in that only 50% of participants had underlying CHD. Patients randomized to n-3 PUFA had a marginally significant reduction in total mortality, a nonsignificant reduction in arrhythmic death, and a significantly lower rate of hospitalizations for ventricular arrhythmia. None of the previously described trials reported any data to suggest that n-3 PUFAs were proarrhythmic in these populations.
So, where do we stand regarding recommendations for n-3 PUFAs? Based on the data available in 2002, the American Heart Association recommended that patients without documented CHD eat a variety of fish, preferably oily fish, at least twice a week. Patients with documented CHD are advised to consume ≈1 g of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acid per day, preferably from oily fish, 29 although EPA+DHA supplements could be considered in consultation with their physician. Does the present study, along with the accumulated experimental and human evidence, present significant cause for concern regarding the safety of these recommendations? It does not appear to be so. There are few data to question the safety of the modest amounts of fish consumption recommended, and the preponderance of the evidence does not support a clinically detectable proarrhythmic effect associated with dosages of n-3 PUFA up to 1 g/d. It is also reassuring that no study has reported a significant increase in total mortality associated with dietary or supplemental n-3 PUFA intake.
However, the antiarrhythmic effects of these agents have not been definitely proved either, and the possibility of proarrhythmia raised by the present study, and other potential unforeseen risks associated with n-3 PUFAs, needs to be further considered in randomized trials. The data previously described illustrate how daunting the task of proving or disproving the antiarrhythmic effects of these agents will be in the modern era. Conclusive data will only come from adequately powered randomized trials with SCD and total mortality end points, which will require larger study populations or improved risk stratification measures to identify a population at a proportionally higher risk for SCD as opposed to other causes of death. In addition, determination of SCD and arrhythmic death is difficult in clinical trials and subject to misclassification, which can be minimized, but not eliminated, by rigorous adjudication methods. Therefore, the effects on total mortality will be more reliable. However, to have a significant impact on total mortality, a sufficiently large proportion of the deaths will need to be sudden or n-3 PUFAs will need to have pleiotropic effects that also affect other causes of death. Finally, the electrophysiological actions of n-3 PUFAs may depend on the dose, substrate, and mechanism underlying SCD. Therefore, results from trials performed in one patient population may not be able to be extrapolated to another population.
Although such randomized trials will be large and expensive to conduct, it is only through such trials that definitive data on the efficacy and risks of n-3 PUFAs will be obtained. It would be unfortunate both to miss the opportunity to prevent SCD with this relatively low-cost intervention and to widely disseminate an intervention that may pose unknown risks to certain subgroups of patients. If n-3 PUFAs do protect against SCD in the setting of ischemia, the public health impact in terms of quantity and quality of life saved has the potential to be large. Therefore, the benefits and risks of omega-3 fatty acids still both require and deserve to be adequately tested in randomized trials. 
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